-
1
-
-
0041669381
-
Pathogenesis of hepatic encephalopathy: New insights from neuroimaging and molecular studies
-
Butterworth RF. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003; 39: 278-285
-
(2003)
J Hepatol
, vol.39
, pp. 278-285
-
-
Butterworth, R.F.1
-
5
-
-
0036829480
-
Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS
-
Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-1171
-
(2002)
Hepatology
, vol.36
, pp. 1163-1171
-
-
Olde Damink, S.W.1
Jalan, R.2
Redhead, D.N.3
Hayes, P.C.4
Deutz, N.E.5
Soeters, P.B.6
-
6
-
-
0023284378
-
Ammonia: Key factor in the pathogenesis of hepatic encephalopathy
-
Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-12
-
(1987)
Neurochem Pathol
, vol.6
, pp. 1-12
-
-
Butterworth, R.F.1
Giguère, J.F.2
Michaud, J.3
Lavoie, J.4
Layrargues, G.P.5
-
7
-
-
0027418895
-
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative
-
Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993; 16: 111-118
-
(1993)
Diagn Microbiol Infect Dis
, vol.16
, pp. 111-118
-
-
Hoover, W.W.1
Gerlach, E.H.2
Hoban, D.J.3
Eliopoulos, G.M.4
Pfaller, M.A.5
Jones, R.N.6
-
8
-
-
0036373262
-
Mechanisms of hyperammonemia
-
Bachmann C. Mechanisms of hyperammonemia. Clin Chem Lab Med 2002; 40: 653-662
-
(2002)
Clin Chem Lab Med
, vol.40
, pp. 653-662
-
-
Bachmann, C.1
-
10
-
-
0037232911
-
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial
-
Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-58
-
(2003)
J Hepatol
, vol.38
, pp. 51-58
-
-
Mas, A.1
Rodés, J.2
Sunyer, L.3
Rodrigo, L.4
Planas, R.5
Vargas, V.6
Castells, L.7
Rodríguez-Martínez, D.8
Fernández-Rodríguez, C.9
Coll, I.10
Pardo, A.11
-
11
-
-
33845383261
-
Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy
-
Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006; 38: 3552-3555
-
(2006)
Transplant Proc
, vol.38
, pp. 3552-3555
-
-
Neff, G.W.1
Kemmer, N.2
Zacharias, V.C.3
Kaiser, T.4
Duncan, C.5
McHenry, R.6
Jonas, M.7
Novick, D.8
Williamson, C.9
Hess, K.10
Thomas, M.11
Buell, J.12
-
12
-
-
0034030150
-
Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: A double-blind, randomized, dose-finding multi-centre study
-
Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 203-208
-
(2000)
Eur J Gastroenterol Hepatol
, vol.12
, pp. 203-208
-
-
Williams, R.1
James, O.F.2
Warnes, T.W.3
Morgan, M.Y.4
-
13
-
-
0027212359
-
Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy
-
Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 109-118
-
(1993)
Curr Med Res Opin
, vol.13
, pp. 109-118
-
-
Bucci, L.1
Palmieri, G.C.2
-
14
-
-
75749116606
-
Review: Rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy
-
Alcorn J. Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. ACP J Club 2008; 149: 11
-
(2008)
ACP J Club
, vol.149
, pp. 11
-
-
Alcorn, J.1
-
15
-
-
77950246404
-
Rifaximin treatment in hepatic encephalopathy
-
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081
-
(2010)
N Engl J Med
, vol.362
, pp. 1071-1081
-
-
Bass, N.M.1
Mullen, K.D.2
Sanyal, A.3
Poordad, F.4
Neff, G.5
Leevy, C.B.6
Sigal, S.7
Sheikh, M.Y.8
Beavers, K.9
Frederick, T.10
Teperman, L.11
Hillebrand, D.12
Huang, S.13
Merchant, K.14
Shaw, A.15
Bortey, E.16
Forbes, W.P.17
-
16
-
-
0022826267
-
In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin
-
Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986; 5: 257-262
-
(1986)
Chemioterapia
, vol.5
, pp. 257-262
-
-
Venturini, A.P.1
Marchi, E.2
-
18
-
-
0028958031
-
Insulin-like growth factors and their binding proteins: Biological actions
-
Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34
-
(1995)
Endocr Rev
, vol.16
, pp. 3-34
-
-
Jones, J.I.1
Clemmons, D.R.2
-
19
-
-
0035015568
-
Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis
-
Fernández-Rodriguez CM, Prada I, Andrade A, Moreiras M, Guitián R, Aller R, Lledó JL, Cacho G, Quiroga J, Prieto J. Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Dig Dis Sci 2001; 46: 1313-1320
-
(2001)
Dig Dis Sci
, vol.46
, pp. 1313-1320
-
-
Fernández-Rodriguez, C.M.1
Prada, I.2
Andrade, A.3
Moreiras, M.4
Guitián, R.5
Aller, R.6
Lledó, J.L.7
Cacho, G.8
Quiroga, J.9
Prieto, J.10
-
20
-
-
0030817309
-
Hepatoprotective effects of insulinlike growth factor I in rats with carbon tetrachlorideinduced cirrhosis
-
Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, Prieto J. Hepatoprotective effects of insulinlike growth factor I in rats with carbon tetrachlorideinduced cirrhosis. Gastroenterology 1997; 113: 1682-1691
-
(1997)
Gastroenterology
, vol.113
, pp. 1682-1691
-
-
Castilla-Cortazar, I.1
Garcia, M.2
Muguerza, B.3
Quiroga, J.4
Perez, R.5
Santidrian, S.6
Prieto, J.7
-
21
-
-
0035978532
-
Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats
-
Muguerza B, Castilla-Cortázar I, García M, Quiroga J, Santidrián S, Prieto J. Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta 2001; 1536: 185-195
-
(2001)
Biochim Biophys Acta
, vol.1536
, pp. 185-195
-
-
Muguerza, B.1
Castilla-Cortázar, I.2
García, M.3
Quiroga, J.4
Santidrián, S.5
Prieto, J.6
-
22
-
-
0030806552
-
Impaired intestinal sugar transport in cirrhotic rats: Correction by low doses of insulin-like growth factor I
-
Castilla-Cortazar I, Prieto J, Urdaneta E, Pascual M, Nuñez M, Zudaire E, Garcia M, Quiroga J, Santidrian S. Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I. Gastroenterology 1997; 113: 1180-1187
-
(1997)
Gastroenterology
, vol.113
, pp. 1180-1187
-
-
Castilla-Cortazar, I.1
Prieto, J.2
Urdaneta, E.3
Pascual, M.4
Nuñez, M.5
Zudaire, E.6
Garcia, M.7
Quiroga, J.8
Santidrian, S.9
-
23
-
-
33747458514
-
Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats
-
Lorenzo-Zúñiga V, Rodríguez-Ortigosa CM, Bartolí R, Martínez-Chantar ML, Martínez-Peralta L, Pardo A, Ojanguren I, Quiroga J, Planas R, Prieto J. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006; 55: 1306-1312
-
(2006)
Gut
, vol.55
, pp. 1306-1312
-
-
Lorenzo-Zúñiga, V.1
Rodríguez-Ortigosa, C.M.2
Bartolí, R.3
Martínez-Chantar, M.L.4
Martínez-Peralta, L.5
Pardo, A.6
Ojanguren, I.7
Quiroga, J.8
Planas, R.9
Prieto, J.10
-
24
-
-
77957138796
-
Rat CCl(4)-induced cirrhosis plus total portal vein ligation: A new model for the study of hyperammonaemia and brain oedema
-
Miquel M, Bartolí R, Odena G, Serafín A, Cabré E, Galan A, Barba I, Córdoba J, Planas R. Rat CCl(4)-induced cirrhosis plus total portal vein ligation: a new model for the study of hyperammonaemia and brain oedema. Liver Int 2010; 30: 979-987
-
(2010)
Liver Int
, vol.30
, pp. 979-987
-
-
Miquel, M.1
Bartolí, R.2
Odena, G.3
Serafín, A.4
Cabré, E.5
Galan, A.6
Barba, I.7
Córdoba, J.8
Planas, R.9
-
25
-
-
0026027619
-
A rodent model of cirrhosis, ascites, and bacterial peritonitis
-
Runyon BA, Sugano S, Kanel G, Mellencamp MA. A rodent model of cirrhosis, ascites, and bacterial peritonitis. Gastroenterology 1991; 100: 489-493
-
(1991)
Gastroenterology
, vol.100
, pp. 489-493
-
-
Runyon, B.A.1
Sugano, S.2
Kanel, G.3
Mellencamp, M.A.4
-
26
-
-
0002079850
-
Animal models of portal hypertension
-
In: Okuda K, Benhamou JP. Portal hypertension. Tokyo: Springer-Verlag
-
Lebrec D. Animal models of portal hypertension. In: Okuda K, Benhamou JP. Portal hypertension. Clinical and Physiological aspects. Tokyo: Springer-Verlag, 1991: 101-113
-
(1991)
Clinical and Physiological aspects
, pp. 101-113
-
-
Lebrec, D.1
-
27
-
-
0030874289
-
Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites
-
Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-1378
-
(1997)
J Hepatol
, vol.26
, pp. 1372-1378
-
-
Guarner, C.1
Runyon, B.A.2
Young, S.3
Heck, M.4
Sheikh, M.Y.5
-
28
-
-
0031054156
-
The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy
-
Vogels BA, van Steynen B, Maas MA, Jörning GG, Chamuleau RA. The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. J Hepatol 1997; 26: 387-395
-
(1997)
J Hepatol
, vol.26
, pp. 387-395
-
-
Vogels, B.A.1
van Steynen, B.2
Maas, M.A.3
Jörning, G.G.4
Chamuleau, R.A.5
-
29
-
-
0026072529
-
Classification of chronic viral hepatitis: A need for reassessment
-
Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374
-
(1991)
J Hepatol
, vol.13
, pp. 372-374
-
-
Scheuer, P.J.1
-
30
-
-
0036451169
-
The role of the liver in the response to LPS: Experimental and clinical findings
-
Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002; 8: 319-327
-
(2002)
J Endotoxin Res
, vol.8
, pp. 319-327
-
-
Jirillo, E.1
Caccavo, D.2
Magrone, T.3
Piccigallo, E.4
Amati, L.5
Lembo, A.6
Kalis, C.7
Gumenscheimer, M.8
-
31
-
-
33745129374
-
Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid
-
Paik YH, Lee KS, Lee HJ, Yang KM, Lee SJ, Lee DK, Han KH, Chon CY, Lee SI, Moon YM, Brenner DA. Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Lab Invest 2006; 86: 676-686
-
(2006)
Lab Invest
, vol.86
, pp. 676-686
-
-
Paik, Y.H.1
Lee, K.S.2
Lee, H.J.3
Yang, K.M.4
Lee, S.J.5
Lee, D.K.6
Han, K.H.7
Chon, C.Y.8
Lee, S.I.9
Moon, Y.M.10
Brenner, D.A.11
-
32
-
-
70350100353
-
Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis
-
1669.e1-1679.e1
-
Zapater P, Caño R, Llanos L, Ruiz-Alcaraz AJ, Pascual S, Barquero C, Moreu R, Bellot P, Horga JF, Muñoz C, Pérez J, García-Peñarrubia P, Pérez-Mateo M, Such J, Francés R. Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis. Gastroenterology 2009; 137: 1669-1679. e1
-
(2009)
Gastroenterology
, vol.137
-
-
Zapater, P.1
Caño, R.2
Llanos, L.3
Ruiz-Alcaraz, A.J.4
Pascual, S.5
Barquero, C.6
Moreu, R.7
Bellot, P.8
Horga, J.F.9
Muñoz, C.10
Pérez, J.11
García-Peñarrubia, P.12
Pérez-Mateo, M.13
Such, J.14
Francés, R.15
-
33
-
-
17544378230
-
Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis
-
Pardo A, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000; 31: 858-863
-
(2000)
Hepatology
, vol.31
, pp. 858-863
-
-
Pardo, A.1
Bartolí, R.2
Lorenzo-Zúñiga, V.3
Planas, R.4
Viñado, B.5
Riba, J.6
Cabré, E.7
Santos, J.8
Luque, T.9
Ausina, V.10
Gassull, M.A.11
-
34
-
-
0035201997
-
Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats
-
Miglioli PA, Allerberger F, Calabrò GB, Gaion RM. Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. Pharmacol Res 2001; 44: 373-375
-
(2001)
Pharmacol Res
, vol.44
, pp. 373-375
-
-
Miglioli, P.A.1
Allerberger, F.2
Calabrò, G.B.3
Gaion, R.M.4
-
35
-
-
37249035165
-
Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS
-
Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53: 169-174
-
(2008)
Dig Dis Sci
, vol.53
, pp. 169-174
-
-
Yang, J.1
Lee, H.R.2
Low, K.3
Chatterjee, S.4
Pimentel, M.5
|